DuPont de Nemours, Inc. (DD) earnings on November 3, 2026
More DuPont de Nemours, Inc. earnings
Prior outlook: Optimistic Outcome: Accurate
DuPont shares rose 8.61% after raising its business forecast, citing stronger orders and faster development linked to AI.
DD price around the earnings
153.46
Change: +8.6%
2026-11-03, 21:00 UTC
- Price: green if it ends above the starting price; red if it ends below
- Start of the measured window
- End of the measured window
- Market open
- Starting price
Prior thesis
Prior outlook: Optimistic Outcome: Accurate
- Thesis published
- Results released
The scenario supports optimism despite strong investor interest
The scenario points optimistic and outweighs more cautious investor sentiment. Analysts cite a roughly $165 price target, and recent earnings surprises support the scenario, though strong investor interest is a caveat.
Context analyzed before publication
- Summary
- The scenario supports optimism despite strong investor interest
- Playbook
- DD has gained 8.8% over 30 days while the broader market fell 2.3%. Analysts cite price targets about 20% above the current price, and the latest four earnings results exceeded expectations.
- Trend
- Expert optimism has risen overall despite daily fluctuations
Analysts
Drivers
-
Analysts
Positive
The average $165 price target is 17.0% above the current price. Most of 17 analyst views are positive, despite one neutral downgrade.
Evidence
- Analyst consensus
- Buy
- Consensus average (1-5)
- 1.61
- Analysts covering the stock
- 17
- Average price target
- 165.29
- Lowest price target
- 145
- Highest price target
- 186
- Upside to price target
- 17%
- Quarterly earnings growth
- 142.4%
- Revenue growth
- 4%
- Forward EPS
- 7.98
- Trailing EPS
- 3.72
- Analyst moves in the last 60 days
- 5
- Strong buy: 3
- Buy: 11
- Hold: 4
- Sell: 0
- Strong sell: 0
- Strong buy
- 3
- Buy
- 11
- Hold
- 4
- Sell
- 0
- Strong sell
- 0
- October 15, 2026 · RBC Capital: Maintains rating (Outperform → Outperform)
- October 13, 2026 · Barclays: Initiates coverage (Overweight)
- October 9, 2026 · JP Morgan: Downgrades rating (Overweight → Neutral)
- October 7, 2026 · Citigroup: Maintains rating (Buy → Buy)
- October 5, 2026 · UBS: Maintains rating (Buy → Buy)
News and sentiment
Drivers
-
News & sentiment
Negative
Nearly 89% of social posts express optimism, making that view crowded. Recent news shows no clear company-specific event that would sharply change earnings expectations.
Evidence
Sentiment
- Sentiment
- Constructive
- Mention volume
- High
- Normalized volume
- 99%
- Messages
- 30
News
Sources (9)
- DuPont Net-Zero Climate Targets Validated by Science Based Targets initiative (opens in a new tab) — fiscal.ai
- DuPont Develops Microplastic-Targeted Probiotic Strains (opens in a new tab) — fiscal.ai
- DuPont Launches AmberChrom™ SIL Silica Gel for Peptide Purification (opens in a new tab) — fiscal.ai
- DuPont Rolls Out DuPont AmberChrom SIL Silica Gel (opens in a new tab) — Benzinga
- DuPont Nutrition & Biosciences Partners with Sedex to Enhance Supply Chain Transparency (opens in a new tab) — fiscal.ai
- Bullard and DuPont Collaborate at SIDEX 2026 (opens in a new tab) — fiscal.ai
- RBC Capital Maintains Outperform on DuPont de Nemours, Lowers Price Target to $160 (opens in a new tab) — Benzinga
- Barclays Initiates Coverage On DuPont de Nemours with Overweight Rating, Announces Price Target of $156 (opens in a new tab) — Benzinga
- JP Morgan Downgrades DuPont de Nemours to Neutral, Lowers Price Target to $145 (opens in a new tab) — Benzinga
Technicals
Drivers
-
Technical
Positive
DD rose 8.8% over 30 days while the broader market fell 2.3%, leaving it ahead by 11.1%.
Evidence
- Price when the context was analyzed
- 141.45
- Average true range (ATR)
- 1.7%
- Distance to 52-week high
- -7.5%
- 14-day change (14d)
- +9.3%
- 30-day change (31d)
- +8.8%
- 30-day relative strength
- +11.1%
- SPY change (31d)
- -2.3%
- Nearest support
- 140.91
- Distance to nearest support
- 0.4%
- Nearest resistance
- 142.02
- Distance to nearest resistance
- 0.4%
- Volume accumulation ratio (14d / 46d)
- 0.9
- Major: 140.91 (0.4% away, 0.23 ATR, 26 touches)
- Mid: 139.8 (1.2% away, 0.7 ATR, 21 touches)
- Major: 139.16 (1.6% away, 0.96 ATR, 37 touches)
- Major: 142.02 (0.4% away, 0.24 ATR, 29 touches)
- Mid: 143.25 (1.3% away, 0.76 ATR, 16 touches)
- Major: 143.92 (1.7% away, 1.03 ATR, 20 touches)
Trends
Evidence
- Average earnings surprise
- +9.5%
- August 4, 2026: actual EPS 1.88 vs estimate 1.76 (surprise +6.8%)
- May 5, 2026: actual EPS 1.65 vs estimate 1.45 (surprise +13.6%)
- February 10, 2026: actual EPS 1.38 vs estimate 1.29 (surprise +6.6%)
- November 6, 2025: actual EPS 3.27 vs estimate 2.94 (surprise +11.2%)
Expected move
Drivers
-
Past earnings
Positive
Earnings per share exceeded estimates by 6.6% to 13.6% in each of the last four reports.
- Implied move
- +2.0%
- Source
- Options chain
Reactions over its last 21 earnings
- Median move
- 4.9%
- 75th percentile move
- 7.4%
- 90th percentile move
- 8.2%
- Up / down moves
- 15 / 6
- Average up move
- +5.3%
- Average down move
- -3.1%
Monitoring and close
What DuPont de Nemours, Inc. reported
- Status
- Finished
| Actual EPS | 2.09 |
|---|---|
| EPS estimate | 1.87 |
| EPS surprise | +11.8% |
| Revenue | $1,868 million |
| Revenue estimate | $1,843 million |
| Revenue surprise | +1.4% |
DuPont beat third-quarter estimates, reporting strong organic growth, improved margins and raising 2026 guidance; a summary of its Q3 2026 earnings call added further detail.
Sources (25)
- DuPont de Nemours, Inc. Q3 2026 Earnings Call Summary (opens in a new tab) — Yahoo
- Fermium Research Maintains Buy on DuPont de Nemours, Raises Price Target to $160 (opens in a new tab) — Benzinga
- DuPont Raises Outlook As Order Book Climbs and AI Cuts Development Time (opens in a new tab) — Benzinga
- DD Q3 Earnings Beat on Organic Growth, Raises 2026 Outlook (opens in a new tab) — Yahoo
- DuPont de Nemours Q3 2026 Earnings Call Transcript (opens in a new tab) — Benzinga
- DuPont Sees 2027 End-Market Conditions Broadly In Line With 2026; Expects Slight Improvement In Automotive Market Conditions In 2027 (opens in a new tab) — Benzinga
- DuPont Sees Q4 Healthcare & Water Organic Sales Growth In The High Single-Digit Percent Range; Sees Q4 Diversified Industrials Organic Sales Growth In The High Single-Digit Percent Range; Says Research & Development Investment Is Shifting Towards Growth Initiatives; Says Share Buyback Pace Will Depend On Timing Of Potential Mergers And Acquisitions (opens in a new tab) — Benzinga
- DuPont Raises 2026 Earnings Outlook After Strong Third-Quarter Results (opens in a new tab) — Yahoo
- DuPont de Nemours (DD) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (opens in a new tab) — Yahoo
- DuPont On Conference Call Sees Q4 Healthcare & Water, Diversified Industrials Organic Sales Growth In High Single Digits; FY Free Cash Flow Conversion About 100%, Above 90% Target (opens in a new tab) — Benzinga
- DuPont de Nemours, Inc. Reports Third Quarter 2026 Net Sales of $1.9 billion (opens in a new tab) — Fintel
- DuPont De Nemours Says Large Middle East Water Projects Will Be Delayed Into 2027 Due To Ongoing Disruptions (opens in a new tab) — Benzinga
- DuPont Reports Third Quarter 2026 Financial Results and Raises Full-Year Outlook (opens in a new tab) — fiscal.ai
- DuPont (NYSE:DD) Q3 Earnings Beat and Raised Guidance Offset In-Line Revenue (opens in a new tab) — ChartMill
- DuPont’s Earnings Outlook Is Improving (opens in a new tab) — Yahoo
- DuPont Q3 Organic Sales Up 5% (opens in a new tab) — Benzinga
- DuPont To Buy Back $250M Of Stock In Q4 (opens in a new tab) — Benzinga
- DuPont Sees FY26 Organic Growth ~4.5% (opens in a new tab) — Benzinga
- DuPont Sees Q4 Adj. EPS $1.90-$1.95, Sales ~$1.825B, Operating EBITDA ~$455M (opens in a new tab) — Benzinga
- DuPont Raises FY26 Adj. EPS Guidance To $7.47-$7.52; Sees FY26 Sales ~$7.19B, Operating EBITDA ~$1.785B (opens in a new tab) — Benzinga
- DuPont de Nemours Sees Q4 Adj EPS $1.90-$1.95 vs $1.87 Est; Sees Sales $1.825B vs $1.824B Est (opens in a new tab) — Benzinga
- DuPont de Nemours Raises FY2026 Adj EPS Guidance from $7.17-$7.32 to $7.47-$7.52 vs $7.25 Est; Raises FY2026 Sales Guidance from $7.160B-$7.190B to $7.190B vs $7.169B Est (opens in a new tab) — Benzinga
- DuPont de Nemours third quarter: adjusted EPS of $2.09 beat the $1.87 estimate, while sales of $1.868B exceeded the $1.843B estimate. — Benzinga
- DuPont de Nemours Q3 Adj. EPS $2.09 Beats $1.87 Estimate, Sales $1.868B Beat $1.843B Estimate (opens in a new tab) — Benzinga
- DuPont Reports Third Quarter 2026 Results (opens in a new tab) — Yahoo
Pre-market second reading after the results
- Verdict
- Beat expectations
Heading into the open, Results beat expectations on both earnings and revenue and the price is indicating +2.4% pre-market, a move below the stock's usual reaction (about 5%). The figures confirm the optimistic scenario. Across our market history, in the 1,671 similar cases the close held that direction 75% of the time.
How the stock reacted
- Outcome
- Accurate
- Consolidated
- +8.6%
- Max favorable move (MFE)
- 10.1%
- Max adverse move (MAE)
- 0%